Creative Medical Technology Holdings Inc - Asset Resilience Ratio
Creative Medical Technology Holdings Inc (CELZ) has an Asset Resilience Ratio of 1.33% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Creative Medical Technology Holdings Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Creative Medical Technology Holdings Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Creative Medical Technology Holdings Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Creative Medical Technology Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Creative Medical Technology Holdings Inc total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $125.00K | 1.33% |
| Total Liquid Assets | $125.00K | 1.33% |
Asset Resilience Insights
- Limited Liquidity: Creative Medical Technology Holdings Inc maintains only 1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Creative Medical Technology Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Creative Medical Technology Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Creative Medical Technology Holdings Inc (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Creative Medical Technology Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $6.67 Million | -- |
| 2023-12-31 | 60.85% | $6.52 Million | $10.72 Million | +8.32pp |
| 2022-12-31 | 52.53% | $10.08 Million | $19.19 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $11.27 Million | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more